Recently, the Shanghai Medical Products Administration released the first batch of drug quality inspection notice for 2024. The notice showed that 12 batches of drugs from 10 pharmaceutical companies, including Shanghai Leiyunshang Traditional Chinese Medicine Decoction Pieces Factory, failed the inspection. These products that do not comply with regulations include: Shegan (moisture) produced by Beijing Qiancao Traditional Chinese Medicine Pieces Co., Ltd., Compound Ketoconazole Hair Wash (microbial limit) produced by Jiangsu Chenpai Bond Pharmaceutical Co., Ltd., Sodium Chloride Injection (visible foreign matter) produced by Jimin Health Management Co., Ltd., Hawthorn (moisture) produced by Changzhou Taihe National Pharmaceutical Products Co., Ltd., Xiebai (content determination) and Polygonum multiflorum (content determination) produced by Shanghai Hongqiao Traditional Chinese Medicine Pieces Co., Ltd., Shajiefeng (content determination) produced by Shanghai Tongji Tang Pharmaceutical Co., Ltd., Stir fried Jujube Kernel (moisture) produced by Shanghai Yanghetang Traditional Chinese Medicine Pieces Co., Ltd., Beehive (aflatoxin) produced by Shanghai Qingpu Traditional Chinese Medicine Pieces Co., Ltd., and Polygonum multiflorum multiflorum (content determination) produced by Shanghai Hongqiao Traditional Chinese Medicine Pieces Co., Ltd. Sichuan Achyranthes Radix produced by Huapu Traditional Chinese Medicine Decoction Pieces Co., Ltd. (characteristics, extract) Shanghai Leiyunshang Traditional Chinese Medicine Decoction Pieces Factory Co., Ltd. produces honey bran fried white peony (sulfur dioxide residue) and Xiebai (moisture). It is worth noting that Shanghai Leiyunshang Traditional Chinese Medicine Decoction Pieces Factory Co., Ltd. is not the first to encounter drug quality issues. In the past few years, the company has been punished by regulatory authorities multiple times for failing drug inspections. On October 25, 2021, Shanghai Sunshine Pharmaceutical Procurement Network released the "Announcement on the Quality Inspection of Some Traditional Chinese Medicine Pieces in 2021 (Phase III)", which showed that the dandelion produced by Shanghai Leiyunshang Traditional Chinese Medicine Pieces Factory Co., Ltd. was unqualified. On January 2, 2018, the Shanghai Food and Drug Administration issued the 8th batch of drug supervision and sampling quality announcement for 2017. The announcement showed that the lotus seed heart (content determination) and white grass root (moisture) of Shanghai Leiyunshang Traditional Chinese Medicine Decoction Pieces Factory Co., Ltd. were unqualified. The notice shows that for batches of products that do not meet the regulations during random inspections, drug regulatory departments at all levels have required relevant enterprises to take risk control measures such as suspension, discontinuation, and recall, and have lawfully investigated and punished the relevant enterprises. The residual amount of sulfur dioxide refers to the determination of the residual amount of sulfur dioxide in medicinal materials or decoction pieces that have been treated with sulfur fumigation. (New Society)